Evommune, Inc. filed an 8-K on November 17, 2026, disclosing that its Compensation Committee approved, on November 13, 2026, a repricing of eligible stock options to $7.63 per share and cash retention awards for three named executive officers.

Key Highlights

  • Option repricing: All Eligible Options were repriced to $7.63 per share, the closing price of Evommune's common stock on November 13, 2026, reduced from exercise prices ranging from $16.00 to $26.77.
  • Total shares affected: The total number of shares underlying all Eligible Options is 3,692,840 shares, according to the filing.
  • CEO retention award: Luis Peña, President and Chief Executive Officer, was approved for a cash retention award of $686,600.
  • CFO retention award: Kyle Carver, Chief Financial Officer, was approved for a cash retention award of $565,000.
  • Chief Business and Legal Officer retention award: Gregory Moss was approved for a cash retention award of $595,000.
  • Stock price condition: The second installment of each retention award requires the company's common stock to reach or exceed $15.00 per share under specified conditions on or before the second anniversary of the amendment effective date.
  • Retention period for repricing: Eligible Participants must remain in Continuous Service through the end of a Retention Period beginning November 13, 2026, and ending no later than 12 months following that date, to exercise options at the reduced price.

Evommune Compensation Committee Approves Option Repricing and Executive Retention Program

According to the filing, Evommune, Inc. (NYSE:EVMN), a Delaware-incorporated company headquartered in Palo Alto, California, disclosed that its Compensation Committee acted on November 13, 2026, to reprice stock options and establish cash retention awards for its senior executive team. The repricing applied to options granted under the company's 2025 Equity Incentive Plan that, as of the repricing effective date, were held by then-current employees and non-employee directors and carried exercise prices at or above $16.00 per share. The new exercise price was set at $7.63 per share, matching the closing price of the company's common stock on that date.

The filing stated that the Committee noted "nearly all of the stock options held by Company employees were 'underwater,' with exercise prices well above the current market price of the Company's common stock." The Committee indicated it designed the repricing, which includes a premium exercise price applicable during the Retention Period for early exercises, to retain and motivate eligible participants without incurring stock dilution from additional equity grants or additional cash expenditures from added cash compensation. No changes were made to vesting schedules, expiration dates, or the number of shares underlying the Eligible Options as a result of the repricing.

Separately, the filing disclosed that amendments to employment agreements for the Chief Executive Officer, Chief Financial Officer, and Chief Business and Legal Officer were approved to allow each to earn cash retention awards payable in two equal installments. The first installment vests on the first anniversary of each officer's amendment effective date, subject to a continuous employment condition. The second installment vests on the second anniversary and is additionally conditioned on the company's stock achieving an average closing price of at or above $15.00 per share during any 15 consecutive trading days after the first anniversary, or a closing price at or above $15.00 on the second anniversary itself. The filing also noted that a Change in Control occurring on or before the second anniversary would cause any unearned portion of the retention awards to become fully earned at closing, provided the officer remains employed through that event.

What Was Disclosed

Evommune's Compensation Committee, on November 13, 2026, approved a repricing of 3,692,840 shares' worth of stock options to $7.63 per share and established cash retention awards of $686,600, $565,000, and $595,000 for the CEO, CFO, and Chief Business and Legal Officer, respectively, subject to specified vesting and stock price conditions.